MiRNA-124-3p.1 sensitizes hepatocellular carcinoma cells to sorafenib by regulating FOXO3a by targeting AKT2 and SIRT1

As a multikinase inhibitor, sorafenib is commonly used to treat patients with advanced hepatocellular carcinoma (HCC), however, acquired resistance to sorafenib is a major obstacle to the effectiveness of this treatment. Thus, in this study, we investigated the mechanisms underlying sorafenib resist...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Zhe-bin, Wu, Heng-miao, He, Yi-cheng, Huang, Zhong-ting, Weng, Yi-hui, Li, Hong, Liang, Chao, Yu, Wei-ming, Chen, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8748751/
https://www.ncbi.nlm.nih.gov/pubmed/35013144
http://dx.doi.org/10.1038/s41419-021-04491-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8748751/
https://www.ncbi.nlm.nih.gov/pubmed/35013144
http://dx.doi.org/10.1038/s41419-021-04491-0

Ejemplares similares